🌍September 15, 2026·3d agoResearch

Patient and Healthcare Professional Attitudes and Trial Experiences with a Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) for Schizophrenia Treatment.

Publisher

Europe PMC

This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: Europe PMC
Region: EU
Scope: Research
Published: September 15, 2026
Language: EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on europepmc.org

Leave the platform to read the original full article on the publisher site.

Source: Europe PMC

Scope: Research

Open original article

Related coverage

More related coverage

Policlinico di Milano/1d ago

[17.09] Il Policlinico di Milano si illumina di arancione per la Giornata Nazionale della Sicurezza delle Cure

Universitätsklinikum Heidelberg/1d ago

Informationstag Pankreaszysten: Wann ist eine Behandlung notwendig?

UNMC/1d ago

MMI marks five years in state-of-the-art building